- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05891249
A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India
A Phase 4 Study to Evaluate Safety and Effectiveness of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic SyndromeS (MDS) With Ring Sideroblasts Who Require Red Blood Cell Transfusions in Subjects Who Have Had Unsatisfactory Response to or Are Ineligible to Erythropoietin Based Therapy and in Subjects With Transfusion Dependent Anemia Due to Beta-Thalassemia
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Contact Backup
- Name: First line of the email MUST contain the NCT# and Site #.
Study Locations
-
-
-
Assam, India, 781032
- Recruiting
- Gauhati Medical College and Hospital
-
Contact:
- Jina Bhattacharyya, Site 0005
- Phone Number: +919435557491
-
Bangalore, India, 560027
- Recruiting
- HealthCare Global Enterprises Ltd. Hospital
-
Contact:
- Sachin Jadhav, Site 0003
- Phone Number: +919741351357
-
Chandigarh, India, 160012
- Recruiting
- Post Graduate Institute of Medical Education and Research
-
Contact:
- Pankaj Malhotra, Site 0004
- Phone Number: 911722756680
-
Delhi, India, 110085
- Recruiting
- Rajiv Gandhi Cancer Institute And Research Centre
-
Contact:
- Dinesh Bhurani, Site 0010
- Phone Number: 9971500861
-
Hyderabad, India, 500034
- Recruiting
- Local Institution - 0006
-
Contact:
- Site 0006
-
Kolkata, India, 700156
- Withdrawn
- Local Institution - 0009
-
Mumbai, India, 400012
- Recruiting
- KEM Hospital and Seth G S Medical College
-
Contact:
- S Chandrakala, Site 0008
- Phone Number: +919322042985
-
-
Delhi
-
New Delhi, Delhi, India, 110029
- Not yet recruiting
- Local Institution - 0001
-
Contact:
- Site 0001
-
New Delhi, Delhi, India, 110029
- Withdrawn
- Local Institution - 0011
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380009
- Recruiting
- Vedanta Institute Of Medical Sciences
-
Contact:
- Sandip A. Shah, Site 0002
- Phone Number: 9824041170
-
-
Karnataka
-
Bengaluru, Karnataka, India, 560027
- Withdrawn
- Local Institution - 0012
-
-
Uttar Pradesh
-
Noida, Uttar Pradesh, India, 201303
- Withdrawn
- Local Institution - 0014
-
-
West Bangal
-
Kolkatta, West Bangal, India, 700014
- Recruiting
- Nilratan Sirkar Medical College and Hospital
-
Contact:
- Tuphan Dolai, Site 0007
- Phone Number: +919874890275
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
β-Thalassemia Cohort
- Documented diagnosis of β-thalassemia or hemoglobin (Hb E/β-thalassemia). (β-thalassemia with mutation and/or multiplication of alpha [α] globin is allowed).
- Regularly transfused, defined as 6 RBC units to 20 RBC units in the 24 weeks prior to enrollment and no transfusion-free period for > 35 days during that period.
MDS-RS Cohort
- Participant has documented diagnosis of MDS according to World Health Organization (WHO) (2016)/French-American-British FAB classification that meets revised International Prognostic Scoring System (IPSS-R) classification of very low, low, or intermediate risk disease and the following criteria: i) RS ≥ 15% of erythroid precursors in bone marrow. If the SF3B1 mutation is present, RS ≥ 5% will be included.
ii) Less than 5% blasts in bone marrow and < 1% peripheral blood blasts. iii) Peripheral blood white blood cell (WBC) count < 13,000/ microliters (μL).
- If the participant was previously treated with erythropoiesis-stimulating agents (ESAs) or granulocyte colony-stimulating factor (G-CSF)/granulocyte-macrophage colony-stimulating factor (GM-CSF), both agents must have been discontinued ≥ 4 weeks prior to the date of enrollment.
Exclusion Criteria:
β-Thalassemia Cohort
- A diagnosis of Hb S/β-thalassemia or α-thalassemia (for exampe, Hemoglobin H).
- Deep vein thrombosis (DVT) or stroke requiring medical intervention ≤ 24 weeks prior to enrollment.
- Use of chronic anticoagulant therapy is excluded unless the treatment stopped at least 28 days prior to enrollment. Anticoagulant therapies used for prophylaxis for surgery or high-risk procedures as well as low-molecular-weight (LMW) heparin for superficial venous thrombosis and chronic aspirin are allowed.
MDS-RS Cohort
- MDS associated with del 5q cytogenetic abnormality.
- Secondary MDS, that is, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation for other diseases.
- Participant has known clinically significant anemia due to iron, vitamin B12, or folate deficiencies; autoimmune or hereditary hemolytic anemia; or gastrointestinal bleeding.
- Iron deficiency to be determined by serum ferritin ≤ 15 micrograms per liter (μg/L) and additional testing if clinically indicated (for example, calculated transferrin saturation [iron/total iron binding capacity ≤ 20%] or bone marrow aspirate [BMA] stain for iron).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Luspatercept
|
Specified dose on specified days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
β-Thal Cohort: Number of participants with treatment-related adverse events (AEs) of grade 3 or higher
Time Frame: Up to 57 weeks
|
Up to 57 weeks
|
MDS-Ring Sideroblasts (RS) Cohort: Number of participants with treatment-related AEs of grade 3 or higher
Time Frame: Up to 54 weeks
|
Up to 54 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
β-Thal Cohort: Percentage of participants who achieved red blood cell (RBC) transfusion burden reduction (≥ 33% reduction from baseline) with a reduction of at least 2 red cell units
Time Frame: Week 13 to week 24
|
Week 13 to week 24
|
β-Thal Cohort: Percentage of participants who achieved RBC transfusion burden reduction of at least 33% from baseline during any 12-week interval with a reduction of at least 2 red cell units
Time Frame: Up to 57 weeks
|
Up to 57 weeks
|
MDS-RS Cohort: Percentage of participants who achieved RBC-TI during any consecutive 56-day period
Time Frame: Week 1 to week 24
|
Week 1 to week 24
|
β-Thal Cohort: Number of participants with treatment-related AEs
Time Frame: Up to 57 weeks
|
Up to 57 weeks
|
MDS-RS Cohort: Number of participants with treatment-related AEs
Time Frame: Up to 54 weeks
|
Up to 54 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CA056-023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
Clinical Trials on Luspatercept
-
University of LeipzigCelgene CorporationRecruitingMyelodysplastic Syndromes | AnemiaGermany
-
Associazione Qol-oneRecruitingMyelodysplastic Syndromes | Anemia | Transfusion-dependent Anemia | Del(5Q)Italy
-
Acceleron Pharma Inc. (a wholly owned subsidiary...Completed
-
Acceleron Pharma Inc. (a wholly owned subsidiary...Completed
-
Acceleron Pharma Inc. (a wholly owned subsidiary...Completed
-
Acceleron Pharma Inc. (a wholly owned subsidiary...CompletedB-ThalassemiaItaly, Greece
-
Sun Yat-sen UniversityRecruitingThalassemia Major | Transfusion-dependent AnemiaChina
-
Groupe Francophone des MyelodysplasiesCelgeneRecruitingMyelodysplastic Syndromes | MDSFrance
-
Hematology department of the 920th hospitalRecruiting
-
Bristol-Myers SquibbRecruitingMyelodysplastic Syndrome | Beta ThalassemiaKorea, Republic of